The FTC is hearing from a lot of doctors.

The agency is starting to ponder new issues in the evolving area of follow-on biologics, a rapidly-growing part of the pharmaceutical industry...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at